Form 8-K Sage Therapeutics, Inc. For: Jul 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sage Therapeutics stock sinks after drug study failed
July 24, 2024 8:15 AM EDTSAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from a late-stage clinical trial for its drug SAGE-324 (BIIB124) for essential tremor (ET).
The Phase 2 KINETIC 2 study failed to meet its primary endpoint, which measured improvement in upper limb tremors. Additionally, no... More
